Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals in the NEWS
Yesterday, Syndax Pharmaceuticals (NASDAQ: SNDX) announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) treated with revumenib, a first-in-class menin inhibitor.

The pediatric data was featured in . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.